Anish Shah, MD
Ophthalmology · Norwich, CTNPI 1528092657
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.0%. Reporting peaked in 2019 at $11,910 and has fallen 93.5% since, to $772 in 2025. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $160.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$8K
- Celularity Inc.$7K
- Eyevance Pharmaceuticals LLC$7K
- Novartis$5K
- Shire North American Group Inc$4K
- Alcon$3K
- plus $5K from 25 others
What the payments were for
- Consulting fees$14,45038%
- Speaking & faculty fees$14,09337%
- Travel & lodging$1,3354%
- Food & beverage$7,83221%
- Education$400%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 14 | $7,575 |
| Celularity Inc. | 6 | $7,301 |
| Eyevance Pharmaceuticals LLC | 16 | $6,911 |
| Novartis | 18 | $4,662 |
| Shire North American Group Inc | 6 | $3,854 |
| Alcon | 28 | $2,971 |
| AbbVie(2 entities) | 38 | $1,495 |
| Amgen(2 entities) | 16 | $310 |
| Kala Pharmaceuticals, Inc. | 14 | $284 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $254 |
| Sun Pharmaceutical Industries Inc. | 9 | $228 |
| Ocular Therapeutix, Inc. | 7 | $227 |
| Dompe US, Inc. | 8 | $206 |
| Hoffmann-la Roche Limited | 2 | $197 |
| Glaukos Corporation | 4 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $149 |
| NEW World Medical,inc. | 2 | $148 |
| Bausch & Lomb Americas Inc. | 7 | $136 |
| Kedrion Biopharma, Inc. | 1 | $104 |
| Beaver-visitec International, Inc. | 2 | $103 |
| Tarsus Pharmaceuticals, Inc. | 3 | $70 |
| Harrow Eye, LLC | 3 | $68 |
| Oyster Point Pharma, Inc. | 3 | $62 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Aerie Pharmaceuticals, Inc. | 4 | $56 |
| Rayner Intraocular Lenses Limited | 2 | $55 |
| Thea Pharma Inc. | 2 | $43 |
| Pacira Pharmaceuticals Incorporated | 2 | $38 |
| Astellas Pharma US Inc | 1 | $36 |
| Omeros Corporation | 2 | $34 |
| Vyera Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$8,141
- OMNI$5,369
- Zerviate$4,000
- Flarex$2,790
- OMNI(R) SURGICAL SYSTEM (US)$2,113
- LenSx$2,039
- Tecnis IOL$373
- ARGOS$291
- XEN GLAUCOMA TREATMENT SYSTEM$278
- ORA$140
- XEN$138
- Ahmed Glaucoma Valve$132
- Kahook Dual Blade$132
- DEXTENZA$121
- DURYSTA$105
- Albuked$104
- KOATE$104
- GAMMAKED$104
- KEDRAB$104
- RhoGAM Ultra-Filtered PLUS$104
How this compares
$37,795 in reported general payments places this provider in the 95th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 311 | $343,276 |
| RestasisCyclosporine | 155 | $178,355 |
| LumiganBimatoprost | 168 | $95,966 |
| Loteprednol Etabonate | 283 | $78,054 |
| Fluorometholone | 607 | $76,179 |
| Cyclosporine | 100 | $41,771 |
| VyzultaLatanoprostene Bunod | 54 | $33,607 |
| InveltysLoteprednol Etabonate | 69 | $33,438 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 115 | $26,497 |
| TyrvayaVarenicline Tartrate | 36 | $22,430 |
| Prednisolone Acetate | 507 | $22,261 |
| LotemaxLoteprednol Etabonate | 43 | $21,311 |
| Azelastine Hcl | 650 | $21,133 |
| ZerviateCetirizine Hcl | 42 | $18,279 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $17,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $136 | $376,883365 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,495 | $291,015357 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax, Alrex, Prolensa, Lotemax Sm | $254 | $119,747376 claims |
| Eyevance Pharmaceuticals LLCZerviate, Flarex, Tobradex St | $6,911 | $37,475124 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $284 | $33,43869 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $56 | $27,50445 claims |
| AlconSimbrinza | $2,971 | $26,497115 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $62 | $22,43036 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $228 | $8,45913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Norwich
- Peter McKayNorwich$3K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
- Madina FalconeFarmington$23K
- Flora LevinBridgeport$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.